The overall objective of this proposal is to establish clinical research sites for three HIV/AIDS Clinical Trials Networks: Vaccine Research and Development, HIV Prevention, and Optimization of Clinical Management, including Co-morbidities.
The specific aims of the NCAIDS CTU are as follows: (1) To conduct clinical trials assessing the safety, immunogenicity, and efficacy of selected candidate HIV-1 vaccines in high-risk populations;(2)To conduct clinical trials evaluating the efficacy and acceptability of promising behavioral and biomedical intervention strategies for preventing HIV transmission in high risk populations;(3)To conduct clinical trials evaluating new therapies against HIV-infection or co-infections with the goal of optimizing the therapeutic effects, increasing medication adherence, elucidating novel mechanisms, and improving features in resistance and toxicological properties;(4)To ensure the clinical trial capability in China adheres to international standards and good clinical practices in order to evaluate strategies for prevention, intervention, and treatment of HIV infection;(5)To further develop the clinical trial infrastructure and enhance the expertise and skills of Chinese investigators, students, and staff to strengthen the HIV prevention and control efforts in China. The main population for the vaccine and prevention research will be intravenous;drug users living in Urumqi City in Xinjiang Autonomous Region, Longchuan County in Yunnan Province, and Shizhong District of Leshan City in Sichuan Province. Research for the optimization of clinical management will be conducted at Beijing Ditan Hospital, Beijing Youan Hospital, and Guangzhou Number 8 People's Hospital in Guangdong Province. These six proposed sites are qualified for implementing clinical trial protocols and have the capacity to enroll sufficient numbers of study subjects. By adhering to good clinical practices, standard operating procedures, and the study protocols, and conducting quality assurance and control measures, the clinical research in the proposed sites will be implemented well and will meet international standards. The HIV epidemic in China has begun to spread from high risk groups to the general population. China urgently needs to join international research aiming at finding new prevention and treatment methods against HIV. Successful implementation of clinical trials on HIV vaccine, behavioral and biomedical prevention, and treatment will greatly assist efforts to control and prevent HIV/AIDS in China and the rest of the world. ADMINISTRATIVE COMPONENT:

National Institute of Health (NIH)
National Institute of Allergy and Infectious Diseases (NIAID)
Research Project with Complex Structure Cooperative Agreement (UM1)
Project #
Application #
Study Section
Special Emphasis Panel (ZAI1-SR-A (M3))
Program Officer
Roth, Lynnea L
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
National Center/AIDS/Std Control/Prevent
Zip Code
Metzger, David S; Donnell, Deborah; Celentano, David D et al. (2015) Expanding substance use treatment options for HIV prevention with buprenorphine-naloxone: HIV Prevention Trials Network 058. J Acquir Immune Defic Syndr 68:554-61
Jackson, J Brooks; Wei, Liu; Liping, Fu et al. (2014) Prevalence and seroincidence of hepatitis B and hepatitis C infection in high risk people who inject drugs in china and Thailand. Hepat Res Treat 2014:296958
Hulgan, Todd; Stein, James H; Cotter, Bruno R et al. (2013) Mitochondrial DNA variation and changes in adiponectin and endothelial function in HIV-infected adults after antiretroviral therapy initiation. AIDS Res Hum Retroviruses 29:1293-9
Wohl, David A; Kendall, Michelle A; Feinberg, Judith et al. (2013) The clinical impact of continuing to prescribe antiretroviral therapy in patients with advanced AIDS who manifest no virologic or immunologic benefit. PLoS One 8:e78676
Bronke, Corine; Almeida, Coral-Ann M; McKinnon, Elizabeth et al. (2013) HIV escape mutations occur preferentially at HLA-binding sites of CD8 T-cell epitopes. AIDS 27:899-905
Huang, Jeannie S; Hughes, Michael D; Riddler, Sharon A et al. (2013) Bone mineral density effects of randomized regimen and nucleoside reverse transcriptase inhibitor selection from ACTG A5142. HIV Clin Trials 14:224-34
Carlson, Jonathan M; Brumme, Chanson J; Martin, Eric et al. (2012) Correlates of protective cellular immunity revealed by analysis of population-level immune escape pathways in HIV-1. J Virol 86:13202-16
Kang, M; Cu-Uvin, S (2012) Association of HIV viral load and CD4 cell count with human papillomavirus detection and clearance in HIV-infected women initiating highly active antiretroviral therapy. HIV Med 13:372-8
Haubrich, Richard H; Riddler, Sharon A; Ribaudo, Heather et al. (2011) Initial viral decay to assess the relative antiretroviral potency of protease inhibitor-sparing, nonnucleoside reverse transcriptase inhibitor-sparing, and nucleoside reverse transcriptase inhibitor-sparing regimens for first-line therapy of HIV infection AIDS 25:2269-78
Umeh, Obi C; Currier, Judith S; Park, Jeong-Gun et al. (2011) Sex differences in lopinavir and ritonavir pharmacokinetics among HIV-infected women and men. J Clin Pharmacol 51:1665-73

Showing the most recent 10 out of 18 publications